RH
XBER:RS1
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
R
|
RH
XBER:RS1
|
US |
|
Maravai LifeSciences Holdings Inc
NASDAQ:MRVI
|
US |
|
Rinnai Corp
TSE:5947
|
JP |
|
Atos SE
PAR:ATO
|
FR |
|
A
|
Azimut Holding SpA
F:HDB
|
IT |
|
Viper Energy Partners LP
NASDAQ:VNOM
|
US |
|
AFK Sistema PAO
MOEX:AFKS
|
RU |
|
C
|
CDL Hospitality Trusts
SGX:J85
|
SG |
|
N
|
NextSource Materials Inc
OTC:NSRCF
|
CA |
|
S
|
SPAR Group Ltd
XBER:S8A
|
ZA |
|
Outlook Therapeutics Inc
NASDAQ:OTLK
|
US |
|
Amgen Inc
NASDAQ:AMGN
|
US |
Wall St Price Targets
RS1 Price Targets Summary
RH
According to Wall Street analysts, the average 1-year price target for RS1 is 161.94 EUR with a low forecast of 94.03 EUR and a high forecast of 266.61 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is RS1's stock price target?
Price Target
161.94
EUR
According to Wall Street analysts, the average 1-year price target for RS1 is 161.94 EUR with a low forecast of 94.03 EUR and a high forecast of 266.61 EUR.
What is the Revenue forecast for RH?
Projected CAGR
9%
Over the last 14 years, the compound annual growth rate for Revenue has been 10%. The projected CAGR for the next 8 years is 9%.
What is the Operating Income forecast for RH?
Projected CAGR
14%
Over the last 14 years, the compound annual growth rate for Operating Income has been 21%. The projected CAGR for the next 8 years is 14%.
What is the Net Income forecast for RH?
Projected CAGR
36%
Over the last 14 years, the compound annual growth rate for Net Income has been 14%. The projected CAGR for the next 8 years is 36%.
